Back in April, it was exciting news to hear that Expesicor and Novoron Bioscience Signed a Collaboration Agreement to Develop Neuro-regenerative Compounds for Epilepsy, Alzheimer’s Disease, and ALS. Now, Expesicor has been awarded a Small Business Innovation Research (SBIR) grant which will has the potential of totaling $1.4 Million dollars over 3 years, to further develop its proprietary KaL model™ of neurodegeneration and epilepsy.

The Daily Inter Lake quoted CEO Braxton Norwood who also shared a “substantial” investment was made by Two Bear Capital, a VC firm based in Whitefish. Investments in our local technology companies fuels job growth and can increase home values in the local area.